RIGL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Rigel Pharmaceuticals Inc (RIGL) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive technical indicators, and favorable options data suggest a solid entry point. While no recent news or congress trading data is available, the company's growth trends and upcoming earnings report provide additional confidence for long-term investment.
The MACD histogram is 0.275, positively expanding and above 0, indicating bullish momentum. The RSI is neutral at 58.283, and moving averages are converging, suggesting a potential breakout. Key support is at 34.023, with resistance at 36.491. The pre-market price of 35.73 is near the pivot level of 35.257, indicating a balanced entry point.
Strong financial performance in Q3 2025 with revenue up 25.59% YoY, net income up 124.62% YoY, and EPS up 108.57% YoY. Gross margin also increased to 93.16%. Upcoming earnings report on 2026-03-04 could act as a catalyst.
No significant hedge fund or insider activity. Lack of recent news or congress trading data.
In Q3 2025, Rigel Pharmaceuticals reported a revenue increase of 25.59% YoY to $69.46M, net income growth of 124.62% YoY to $27.9M, and EPS growth of 108.57% YoY to 1.46. Gross margin improved to 93.16%, up 8.97% YoY, indicating strong profitability and operational efficiency.
No recent analyst ratings or price target changes available for review.
